Skip Navigation
Skip to contents

JYMS : Journal of Yeungnam Medical Science

Indexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge

Author index

Page Path
HOME > Browse Articles > Author index
Suji Kim 1 Article
Therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis
Suji Kim, Jae Hyang Lim, Chang-Hoon Woo
Yeungnam Univ J Med. 2020;37(4):269-276.   Published online July 22, 2020
  • 9,108 View
  • 244 Download
  • 4 Crossref
AbstractAbstract PDF
Fibrosis is characterized by excessive accumulation of extracellular matrix components. The fibrotic process ultimately leads to organ dysfunction and failure in chronic inflammatory and metabolic diseases such as pulmonary fibrosis, advanced kidney disease, and liver cirrhosis. Idiopathic pulmonary fibrosis (IPF) is a common form of progressive and chronic interstitial lung disease of unknown etiology. Pathophysiologically, the parenchyma of the lung alveoli, interstitium, and capillary endothelium becomes scarred and stiff, which makes breathing difficult because the lungs have to work harder to transfer oxygen and carbon dioxide between the alveolar space and bloodstream. The transforming growth factor beta (TGF-) signaling pathway plays an important role in the pathogenesis of pulmonary fibrosis and scarring of the lung tissue. Recent clinical trials focused on the development of pharmacological agents that either directly or indirectly target kinases for the treatment of IPF. Therefore, to develop therapeutic targets for pulmonary fibrosis, it is essential to understand the key factors involved in the pathogenesis of pulmonary fibrosis and the underlying signaling pathway. The objective of this review is to discuss the role of kinase signaling cascades in the regulation of either TGF--dependent or other signaling pathways, including Rho-associated coiled-coil kinase, c-jun N-terminal kinase, extracellular signal-regulated kinase 5, and p90 ribosomal S6 kinase pathways, and potential therapeutic targets in IPF.


Citations to this article as recorded by  
  • Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis
    Hongbo Ma, Shengming Liu, Shanrui Li, Yong Xia
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Vitamin D3 alleviates pulmonary fibrosis by regulating the MAPK pathway via targeting PSAT1 expression in vivo and in vitro
    Wenxiang Zhu, Qi Ding, Lu Wang, Gonghao Xu, Yirui Diao, Sihao Qu, Sheng Chen, Yuanyuan Shi
    International Immunopharmacology.2021; 101: 108212.     CrossRef
  • Advances in the science and treatment of respiratory diseases
    Jin Hong Chung
    Yeungnam University Journal of Medicine.2020; 37(4): 251.     CrossRef
  • Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
    Alessandro G. Fois, Elisabetta Sotgiu, Valentina Scano, Silvia Negri, Sabrina Mellino, Elisabetta Zinellu, Pietro Pirina, Gianfranco Pintus, Ciriaco Carru, Arduino A. Mangoni, Angelo Zinellu
    Antioxidants.2020; 9(11): 1064.     CrossRef

JYMS : Journal of Yeungnam Medical Science